Scarica l'app Stockscreener
1.74
8.42%
-0.16
Dopo l'orario di chiusura:
1.83
0.09
+5.17%
Precedente Chiudi:
$1.90
Aprire:
$1.85
Volume 24 ore:
94,403
Relative Volume:
1.06
Capitalizzazione di mercato:
$25.33M
Reddito:
$1.03M
Utile/perdita netta:
$-13.40M
Rapporto P/E:
-1.3069
EPS:
-1.3314
Flusso di cassa netto:
$-10.27M
1 W Prestazione:
+15.23%
1M Prestazione:
+8.07%
6M Prestazione:
-19.07%
1 anno Prestazione:
-40.21%
Intervallo 1D:
$1.695
$1.865
Intervallo di 1 settimana:
$1.49
$1.91
Portata 52W:
$1.27
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Nome
Dare Bioscience Inc
Settore
Industria
Telefono
858-926-7655
Indirizzo
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.74 | 25.33M | 1.03M | -13.40M | -10.27M | -1.3314 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Head-To-Head Review: Dare Bioscience (NASDAQ:DARE) & Appili Therapeutics (OTCMKTS:APLIF) - Defense World
Maxim Group Upgrades Daré Bioscience (DARE) - MSN
Dare Bioscience, Inc. (DARE) reports Q4 loss, lags revenue estimates - MSN
Dare Bioscience Q4 2025 Earnings Call Transcript - MarketBeat
Transcript : Daré Bioscience, Inc., 2025 Earnings Call, Mar 26, 2026 - MarketScreener
Dare Bioscience, Inc. (DARE) Announces Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Dare Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Daré Bioscience Q4 2025 highlights capital efficiency By Investing.com - Investing.com India
Earnings call transcript: Daré Bioscience Q4 2025 highlights capital efficiency - Investing.com
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Daré Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:DARE) 2026-03-26 - Seeking Alpha
Q4 2025 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
Daré Bioscience (NASDAQ: DARE) expands dual-path women’s health model - Stock Titan
Daré Bioscience (NASDAQ: DARE) details 2025 loss, funding boost and upcoming product launches - stocktitan.net
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Dare Bioscience FY 2025 earnings preview - MSN
Daré Bioscience, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Dare Bioscience Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
A Viagra ingredient is now in a topical cream developed for women - Stock Titan
On National Viagra Day, Women Finally Claim Their Turn: - ChartMill
Dare Bioscience (DARE) Expected to Announce Earnings on Monday - Defense World
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 - The Manila Times
Daré Bioscience, Inc. to Host Conference Call on March 26, 2026, for Year-End Financial Results and Company Update - Quiver Quantitative
Daré Bioscience schedules March 26 webcast for 2025 results - stocktitan.net
DARE BIOSCIENCE, INC. Files Form 8-K with SEC Reporting Unregistered Sale of Equity Securities - Minichart
Dare Bioscience completes closing of Regulation A equity offering By Investing.com - Investing.com Australia
Dare Bioscience secures NIH funding extension for preterm birth therapy - MSN
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience Completes Regulation A Preferred Stock Offering - TipRanks
Daré Bioscience (DARE) issues 43,050 preferred-and-warrant units - Stock Titan
Daré Bioscience extends NIH grant period for preterm birth drug By Investing.com - Investing.com Australia
DARE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dare Bioscience (DARE) Advances Investigational Preterm Birth Tr - GuruFocus
Dare Bioscience receives NIH funding extension for preterm birth treatment By Investing.com - Investing.com Australia
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - manilatimes.net
NIH funds hormone ring as preterm birth lacks FDA-approved treatment - Stock Titan
Daré Bioscience Participates in Virtual Investor “What This Means” Segment - Sahm
Dare Bioscience Participates in Virtual Investor "What This Means" Segment - Bitget
Persistent HPV has no FDA-approved drug; Daré CEO lays out DARE-HPV trial plan - Stock Titan
Daré Bioscience Participates in Virtual Investor 'What This Means” Segment - The Manila Times
Daré Bioscience Completes Second Closing of Regulation A Offering - TipRanks
Daré Bioscience (NASDAQ: DARE) advances Regulation A unit offering - Stock Titan
Daré Bioscience Updates Investor Presentation Under Regulation FD - TipRanks
Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K - Stock Titan
DARE Should I Buy - Intellectia AI
DARE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Daré Bioscience gets FDA clearance for HPV treatment trial By Investing.com - Investing.com India
Daré Bioscience gets FDA clearance for HPV treatment trial - Investing.com Australia
Dare Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Bitget
Dare Bioscience Inc Azioni (DARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):